EVOLUTIONARY RELATIONSHIP AND REPURPOSING OF SARS INHIBITORS AGAINST SURFACE GLYCOPROTEIN OF SARS-COV-2

PRIYANKA RAJBHAR; DIKSHANT SINGH; RUKHSAR FATIMA; RUCHI YADAV

doi:10.22159/ijap.2021v13i5.42652

Authors

PRIYANKA RAJBHAR Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Lucknow 226028
DIKSHANT SINGH Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Lucknow 226028
RUKHSAR FATIMA Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Lucknow 226028
RUCHI YADAV Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Lucknow 226028

DOI:

https://doi.org/10.22159/ijap.2021v13i5.42652

Keywords:

COVID 19, SARS, MERS, Phylogenetic analysis, Spike glycoprotein, Homology modelling, Docking

Abstract

Objective: Coronaviruses are a group of similar viruses which cause fatal infection and responsible for affecting the upper respiratory tract in many organisms. Throughout the time these viruses have been found to affect human life by causing major pandemics like SARS, MERS and COVID-19 due to their high rate of mutation and zoonotic transmission. Repurposing of a drug could be a solution for this challenge, as many previously available drugs hold great potential to act as a drug molecule. Interfering this interaction could be a potent mechanism to stop the viral infection and propagation.

Methods: In the current study we have predicted the evolutionary relationship of nCoV using three viral proteins Nucleocapsid phosphoprotein, membrane glycoprotein and Envelop protein with accession number YP_009724397, YP_009724393 and YP_009724392 respectively. Phylogenetic tree was constructed and evaluated using the bootstrap method. Homology modeling and docking studies has been done to identify the interaction and binding affinity of SARS drugs.

Results: Phylogenetic tree shows that Nucleocapsid phosphoprotein is originated from Hypsugo Bat Coronavirus, Membrane glycoprotein is originated from MERS Corona Virus and Envelop proteins have originated from Ferret coronavirus. From the docking result we concluded that Precose (glide score-8.372) shows that it has stable and strong interaction with Spike glycoprotein.

Conclusion: Precose which is commonly known as Acarbose can act as a potential inhibitor for the spike glycoprotein. This paper described and highlighted the importance of repurposing of the previously available drug to act as a potent inhibitor in the newly discovered or novel diseases.

Downloads

Download data is not yet available.

References

Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020;581:221-4.

Sakurai A, Sasaki T, Kato S, Hayashi M, Tsuzuki SI, Ishihara T, et al. Natural history of asymptomatic SARS-CoV-2 infection. New England J Med 2020;27:885-6.

Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al. Genomic evidence for reinfection with SARS-CoV-2:a case study. Lancet Infect Dis 2021;21:52-8.

Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H. The architecture of SARS-CoV-2 transcriptome. Cell 2020;181:914-21.

Helms J, Kremer S, Merdji H, Clere Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 infection. New England J Med 2020;382:2268-70.

Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020;581:215-20.

Zhou L, Zhang M, Wang J, Gao J. Sars-Cov-2: underestimated damage to nervous system. Travel Med Infect Dis 2020;36:101642.

Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nature Rev Microbiol 2020;6:1-4.

Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, et al. Rapid, point‐of‐care antigen and molecular‐based tests for diagnosis of SARS‐CoV‐2 infection. Cochrane Database Systematic Rev 2021;3. https://doi.org/10.1002/14651858.CD013705.pub2

Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020;158:1831-3.

Helms J, Kremer S, Merdji H, Clere Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 infection. New England J Med 2020;382:2268-70.

Hosier H, Farhadian SF, Morotti RA, Deshmukh U, Lu-Culligan A, Campbell KH, et al. SARS–CoV-2 infection of the placenta. J Clin Investigation 2020;130:4947-53.

Yurkovetskiy L, Wang X, Pascal KE, Tomkins Tinch C, Nyalile TP, Wang Y, et al. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell 2020;183:739-51.

Heydarabadi FH, Baessi K, Bashar R, Fazeli M, Sheikholeslami F. A phylogenetic study of new rabies virus strains in different regions of Iran. Virus Genes 2020;56:361-8.

Miccio Fonseca LC. MEGA♪ Tool: an analysis of “Risk/Treatment needs and progress protocol” by Kang, Beltrani, Manheim, Spriggs, Nishimura, Sinclair, Stachniuk, Pate, Righthand, Prentky, and Worling. J Child Sexual Abuse 2020;29:351-72.

Simon C. An evolving view of phylogenetic support. Syst Biol 2020. DOI:10.1093/sysbio/syaa068

Bhachoo J, Beuming T. Investigating protein–peptide interactions using the schrodinger computational suite. Modeling Peptide Protein Interactions; 2017. p. 235-54.

Reddy KK, Rathore RS, Srujana P, Burri RR, Reddy CR, Sumakanth M, et al. Performance evaluation of docking programs-Glide, GOLD, AutoDock and SurflexDock, using free energy perturbation reference data: a case study of fructose-1, 6-bisphosphatase-AMP analogs. Mini Rev Med Chem 2020;20:1179-87.

Grazina L, Costa J, Amaral JS, Mafra I. High-resolution melting analysis as a tool for plant species authentication. In: Crop Breeding; 2021. p. 55-73.

Kaur J, Famta P, Khurana N, Vyas M, Khatik GL. Pharmacotherapy of type 2 diabetes. In: Obesity and Diabetes Springer; 2020. p. 679-94.